Tags: Drug.

Telcagepant (formerly MK-0974) was an investigational drug for the acute treatment and prevention of migraine developed by Merck & Co. In the acute treatment of migraine it was found to have equal potency to rizatriptan and zolmitriptan in two Phase III clinical trials. The company has now terminated development of the drug.

Telcagepant_structure.svg
ATC prefix
none
CAS number
781649-09-0
FDA UNII code
D42O649ALL
IUPAC name
N-[(3R6S)-6-(23-Difluorophenyl)hexahydro-2-oxo-1-(222-trifluoroethyl)-1H-azepin-3-yl]-4-(23-dihydro-2-oxo-1H-imidazo[45-b]pyridin-1-yl)-1-piperidinecarboxamide
PubChem
11319053

Loading...

This page contains content from the copyrighted Wikipedia article "Telcagepant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.